Molecular Strategies for RPGR Gene Therapy

Area of Science:

• Genetics and Ophthalmology
• Molecular Biology
• Gene Therapy

Background:

• Mutations in the Retinitis Pigmentosa GTPase Regulator (RPGR) gene are a leading cause of X-linked retinitis pigmentosa (RP), a severe inherited retinal disease.
• RPGR-related RP presents with early onset and rapid vision loss, with no current cure.
• Recent research has significantly advanced understanding of RPGR function and therapeutic strategies.

Purpose of the Study:

• To review recent advances in RPGR research, focusing on molecular mechanisms and therapeutic developments.
• To highlight the connection between RPGR protein function, glutamylation, and photoreceptor ciliary transport.
• To discuss pre-clinical research addressing challenges in gene therapy vector development for RPGR.

Main Methods:

• Review of molecular research linking RPGR to glutamylation and photoreceptor function.
• Analysis of pre-clinical studies on adeno-associated viral (AAV) vector development for RPGR gene replacement.
• Examination of the design and rationale of ongoing phase I/II clinical trials for RPGR-related retinal disease.

Main Results:

• RPGR protein's critical role in photoreceptor ciliary transport is linked to glutamylation.
• Pre-clinical studies have identified and addressed challenges related to RPGR genomic sequence fidelity in AAV vector development.
• Three distinct AAV vectors are being evaluated in current clinical trials for RPGR-related RP.

Conclusions:

• Advances in understanding RPGR molecular function and gene therapy vector development are paving the way for potential treatments.
• Ongoing clinical trials represent a significant step towards addressing the unmet need for RPGR-related retinal disease therapies.
• The research bridges fundamental science discoveries with clinical applications for a severe form of retinitis pigmentosa.